nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—ABCB1—peripheral nervous system neoplasm	0.117	1	CbGaD
Sorafenib—RALBP1—Vincristine—peripheral nervous system neoplasm	0.113	0.211	CbGbCtD
Sorafenib—RALBP1—Doxorubicin—peripheral nervous system neoplasm	0.0705	0.132	CbGbCtD
Sorafenib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0251	0.047	CbGbCtD
Sorafenib—UGT1A1—Etoposide—peripheral nervous system neoplasm	0.0178	0.0334	CbGbCtD
Sorafenib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0174	0.0326	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0172	0.0323	CbGbCtD
Sorafenib—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0172	0.0323	CbGbCtD
Sorafenib—CYP2B6—Tretinoin—peripheral nervous system neoplasm	0.0164	0.0307	CbGbCtD
Sorafenib—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0129	0.0242	CbGbCtD
Sorafenib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0124	0.0233	CbGbCtD
Sorafenib—ABCC2—Vincristine—peripheral nervous system neoplasm	0.0118	0.0222	CbGbCtD
Sorafenib—ABCC2—Cisplatin—peripheral nervous system neoplasm	0.011	0.0207	CbGbCtD
Sorafenib—ABCC2—Etoposide—peripheral nervous system neoplasm	0.0108	0.0203	CbGbCtD
Sorafenib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0107	0.0201	CbGbCtD
Sorafenib—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0103	0.0194	CbGbCtD
Sorafenib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.00998	0.0187	CbGbCtD
Sorafenib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.00981	0.0184	CbGbCtD
Sorafenib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.00904	0.0169	CbGbCtD
Sorafenib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.00904	0.0169	CbGbCtD
Sorafenib—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.00866	0.0162	CbGbCtD
Sorafenib—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.00826	0.0155	CbGbCtD
Sorafenib—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.0079	0.0148	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.0079	0.0148	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—peripheral nervous system neoplasm	0.0074	0.0139	CbGbCtD
Sorafenib—CYP2B6—Cisplatin—peripheral nervous system neoplasm	0.00702	0.0132	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.00669	0.0125	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.00626	0.0117	CbGbCtD
Sorafenib—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.00593	0.0111	CbGbCtD
Sorafenib—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.00543	0.0102	CbGbCtD
Sorafenib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00542	0.0101	CbGbCtD
Sorafenib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.00522	0.00979	CbGbCtD
Sorafenib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00503	0.00944	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—peripheral nervous system neoplasm	0.0047	0.00881	CbGbCtD
Sorafenib—Regorafenib—NTRK1—peripheral nervous system neoplasm	0.00405	0.799	CrCbGaD
Sorafenib—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00404	0.00758	CbGbCtD
Sorafenib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00386	0.00723	CbGbCtD
Sorafenib—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00371	0.00695	CbGbCtD
Sorafenib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0036	0.00674	CbGbCtD
Sorafenib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00354	0.00663	CbGbCtD
Sorafenib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00241	0.00452	CbGbCtD
Sorafenib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00231	0.00433	CbGbCtD
Sorafenib—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00227	0.00426	CbGbCtD
Sorafenib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00212	0.00397	CbGbCtD
Sorafenib—MAPK15—brainstem—peripheral nervous system neoplasm	0.00161	0.0628	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00144	0.00271	CbGbCtD
Sorafenib—EPHX2—parotid gland—peripheral nervous system neoplasm	0.000723	0.0283	CbGeAlD
Sorafenib—FGFR1—trigeminal ganglion—peripheral nervous system neoplasm	0.000682	0.0267	CbGeAlD
Sorafenib—HTR2C—ganglion—peripheral nervous system neoplasm	0.000675	0.0264	CbGeAlD
Sorafenib—MAP3K7—trigeminal ganglion—peripheral nervous system neoplasm	0.000646	0.0253	CbGeAlD
Sorafenib—MKNK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000626	0.0245	CbGeAlD
Sorafenib—MKNK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000618	0.0242	CbGeAlD
Sorafenib—RET—trigeminal ganglion—peripheral nervous system neoplasm	0.00061	0.0239	CbGeAlD
Sorafenib—MAP3K7—parotid gland—peripheral nervous system neoplasm	0.000609	0.0238	CbGeAlD
Sorafenib—MKNK2—parotid gland—peripheral nervous system neoplasm	0.00059	0.0231	CbGeAlD
Sorafenib—Regorafenib—ABCB1—peripheral nervous system neoplasm	0.000568	0.112	CrCbGaD
Sorafenib—RALBP1—trigeminal ganglion—peripheral nervous system neoplasm	0.000565	0.0221	CbGeAlD
Sorafenib—FLT1—trigeminal ganglion—peripheral nervous system neoplasm	0.000538	0.021	CbGeAlD
Sorafenib—RAF1—trigeminal ganglion—peripheral nervous system neoplasm	0.000534	0.0209	CbGeAlD
Sorafenib—RALBP1—parotid gland—peripheral nervous system neoplasm	0.000533	0.0209	CbGeAlD
Sorafenib—EPHB6—trigeminal ganglion—peripheral nervous system neoplasm	0.000531	0.0208	CbGeAlD
Sorafenib—CDK7—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000517	0.173	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000517	0.173	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000517	0.173	CbGdCrCtD
Sorafenib—STK10—trigeminal ganglion—peripheral nervous system neoplasm	0.000509	0.0199	CbGeAlD
Sorafenib—FLT1—parotid gland—peripheral nervous system neoplasm	0.000507	0.0198	CbGeAlD
Sorafenib—RAF1—parotid gland—peripheral nervous system neoplasm	0.000504	0.0197	CbGeAlD
Sorafenib—EPHB6—parotid gland—peripheral nervous system neoplasm	0.000501	0.0196	CbGeAlD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000478	0.16	CbGdCrCtD
Sorafenib—CDK7—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000478	0.16	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000478	0.16	CbGdCrCtD
Sorafenib—RAF1—brainstem—peripheral nervous system neoplasm	0.000473	0.0185	CbGeAlD
Sorafenib—MAPK11—cerebellum—peripheral nervous system neoplasm	0.000469	0.0184	CbGeAlD
Sorafenib—CDK7—cerebellum—peripheral nervous system neoplasm	0.000462	0.0181	CbGeAlD
Sorafenib—TAOK2—cerebellum—peripheral nervous system neoplasm	0.000458	0.0179	CbGeAlD
Sorafenib—KDR—trigeminal ganglion—peripheral nervous system neoplasm	0.000454	0.0178	CbGeAlD
Sorafenib—MAP2K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000454	0.0178	CbGeAlD
Sorafenib—Vismodegib—ABCB1—peripheral nervous system neoplasm	0.000451	0.0888	CrCbGaD
Sorafenib—CSF1R—trigeminal ganglion—peripheral nervous system neoplasm	0.000444	0.0174	CbGeAlD
Sorafenib—MAP2K5—parotid gland—peripheral nervous system neoplasm	0.000429	0.0168	CbGeAlD
Sorafenib—KDR—parotid gland—peripheral nervous system neoplasm	0.000429	0.0168	CbGeAlD
Sorafenib—KIT—trigeminal ganglion—peripheral nervous system neoplasm	0.000403	0.0158	CbGeAlD
Sorafenib—MAP2K5—brainstem—peripheral nervous system neoplasm	0.000402	0.0157	CbGeAlD
Sorafenib—ZAK—cerebellum—peripheral nervous system neoplasm	0.000399	0.0156	CbGeAlD
Sorafenib—PDGFRB—trigeminal ganglion—peripheral nervous system neoplasm	0.000393	0.0154	CbGeAlD
Sorafenib—HIPK3—cerebellum—peripheral nervous system neoplasm	0.000391	0.0153	CbGeAlD
Sorafenib—KIT—parotid gland—peripheral nervous system neoplasm	0.00038	0.0149	CbGeAlD
Sorafenib—PDGFRB—parotid gland—peripheral nervous system neoplasm	0.000371	0.0145	CbGeAlD
Sorafenib—TIE1—cerebellum—peripheral nervous system neoplasm	0.000365	0.0143	CbGeAlD
Sorafenib—KIT—brainstem—peripheral nervous system neoplasm	0.000356	0.0139	CbGeAlD
Sorafenib—BRAF—cerebellum—peripheral nervous system neoplasm	0.00035	0.0137	CbGeAlD
Sorafenib—EPHX2—cerebellum—peripheral nervous system neoplasm	0.000334	0.0131	CbGeAlD
Sorafenib—FLT3—cerebellum—peripheral nervous system neoplasm	0.000332	0.013	CbGeAlD
Sorafenib—FGFR1—cerebellum—peripheral nervous system neoplasm	0.000298	0.0116	CbGeAlD
Sorafenib—HTR2C—brainstem—peripheral nervous system neoplasm	0.000293	0.0115	CbGeAlD
Sorafenib—MAP3K7—cerebellum—peripheral nervous system neoplasm	0.000282	0.011	CbGeAlD
Sorafenib—MKNK2—cerebellum—peripheral nervous system neoplasm	0.000273	0.0107	CbGeAlD
Sorafenib—MKNK1—cerebellum—peripheral nervous system neoplasm	0.00027	0.0106	CbGeAlD
Sorafenib—RET—cerebellum—peripheral nervous system neoplasm	0.000266	0.0104	CbGeAlD
Sorafenib—RALBP1—cerebellum—peripheral nervous system neoplasm	0.000247	0.00965	CbGeAlD
Sorafenib—FLT1—cerebellum—peripheral nervous system neoplasm	0.000235	0.00918	CbGeAlD
Sorafenib—RAF1—cerebellum—peripheral nervous system neoplasm	0.000233	0.00913	CbGeAlD
Sorafenib—EPHB6—cerebellum—peripheral nervous system neoplasm	0.000232	0.00907	CbGeAlD
Sorafenib—STK10—cerebellum—peripheral nervous system neoplasm	0.000222	0.00869	CbGeAlD
Sorafenib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000221	0.00865	CbGeAlD
Sorafenib—PDGFRA—cerebellum—peripheral nervous system neoplasm	0.00022	0.0086	CbGeAlD
Sorafenib—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000209	0.00816	CbGeAlD
Sorafenib—MAP2K5—cerebellum—peripheral nervous system neoplasm	0.000198	0.00776	CbGeAlD
Sorafenib—KDR—cerebellum—peripheral nervous system neoplasm	0.000198	0.00776	CbGeAlD
Sorafenib—CSF1R—cerebellum—peripheral nervous system neoplasm	0.000194	0.00757	CbGeAlD
Sorafenib—KIT—cerebellum—peripheral nervous system neoplasm	0.000176	0.00688	CbGeAlD
Sorafenib—PDGFRB—cerebellum—peripheral nervous system neoplasm	0.000172	0.00672	CbGeAlD
Sorafenib—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000134	0.00525	CbGeAlD
Sorafenib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000109	0.00427	CbGeAlD
Sorafenib—ABCG2—cerebellum—peripheral nervous system neoplasm	9.65e-05	0.00378	CbGeAlD
Sorafenib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	9.14e-05	0.000515	CcSEcCtD
Sorafenib—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	9.13e-05	0.000514	CcSEcCtD
Sorafenib—Headache—Tretinoin—peripheral nervous system neoplasm	9.13e-05	0.000514	CcSEcCtD
Sorafenib—Headache—Isotretinoin—peripheral nervous system neoplasm	9.13e-05	0.000514	CcSEcCtD
Sorafenib—Hypertension—Etoposide—peripheral nervous system neoplasm	9.12e-05	0.000514	CcSEcCtD
Sorafenib—Constipation—Vincristine—peripheral nervous system neoplasm	9.1e-05	0.000512	CcSEcCtD
Sorafenib—Pain—Vincristine—peripheral nervous system neoplasm	9.1e-05	0.000512	CcSEcCtD
Sorafenib—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	9.09e-05	0.000512	CcSEcCtD
Sorafenib—Rash—Melphalan—peripheral nervous system neoplasm	9.07e-05	0.000511	CcSEcCtD
Sorafenib—Dermatitis—Melphalan—peripheral nervous system neoplasm	9.06e-05	0.00051	CcSEcCtD
Sorafenib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	9.03e-05	0.000509	CcSEcCtD
Sorafenib—Dry skin—Epirubicin—peripheral nervous system neoplasm	9.01e-05	0.000508	CcSEcCtD
Sorafenib—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	8.98e-05	0.000506	CcSEcCtD
Sorafenib—Anorexia—Cisplatin—peripheral nervous system neoplasm	8.97e-05	0.000505	CcSEcCtD
Sorafenib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	8.94e-05	0.000504	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	8.93e-05	0.000503	CcSEcCtD
Sorafenib—Breast disorder—Epirubicin—peripheral nervous system neoplasm	8.88e-05	0.0005	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	8.85e-05	0.000499	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	8.85e-05	0.000499	CcSEcCtD
Sorafenib—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	8.79e-05	0.000495	CcSEcCtD
Sorafenib—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	8.77e-05	0.000494	CcSEcCtD
Sorafenib—Urticaria—Alitretinoin—peripheral nervous system neoplasm	8.77e-05	0.000494	CcSEcCtD
Sorafenib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	8.73e-05	0.000492	CcSEcCtD
Sorafenib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	8.73e-05	0.000492	CcSEcCtD
Sorafenib—Nausea—Topotecan—peripheral nervous system neoplasm	8.72e-05	0.000491	CcSEcCtD
Sorafenib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	8.7e-05	0.00049	CcSEcCtD
Sorafenib—Gastritis—Epirubicin—peripheral nervous system neoplasm	8.7e-05	0.00049	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	8.67e-05	0.000488	CcSEcCtD
Sorafenib—Nausea—Tretinoin—peripheral nervous system neoplasm	8.65e-05	0.000487	CcSEcCtD
Sorafenib—Nausea—Isotretinoin—peripheral nervous system neoplasm	8.65e-05	0.000487	CcSEcCtD
Sorafenib—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	8.62e-05	0.000485	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—peripheral nervous system neoplasm	8.61e-05	0.000485	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	8.57e-05	0.000483	CcSEcCtD
Sorafenib—Infection—Etoposide—peripheral nervous system neoplasm	8.56e-05	0.000482	CcSEcCtD
Sorafenib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	8.54e-05	0.000481	CcSEcCtD
Sorafenib—Nausea—Melphalan—peripheral nervous system neoplasm	8.54e-05	0.000481	CcSEcCtD
Sorafenib—Dysphagia—Epirubicin—peripheral nervous system neoplasm	8.49e-05	0.000479	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	8.46e-05	0.000476	CcSEcCtD
Sorafenib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	8.44e-05	0.000475	CcSEcCtD
Sorafenib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	8.41e-05	0.000474	CcSEcCtD
Sorafenib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	8.41e-05	0.000474	CcSEcCtD
Sorafenib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	8.39e-05	0.000472	CcSEcCtD
Sorafenib—Skin disorder—Etoposide—peripheral nervous system neoplasm	8.37e-05	0.000472	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	8.33e-05	0.00047	CcSEcCtD
Sorafenib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	8.33e-05	0.000469	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	8.31e-05	0.000468	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	8.28e-05	0.000466	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	8.22e-05	0.000463	CcSEcCtD
Sorafenib—Anorexia—Etoposide—peripheral nervous system neoplasm	8.21e-05	0.000463	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	8.19e-05	0.000461	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.19e-05	0.000461	CcSEcCtD
Sorafenib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	8.18e-05	0.000461	CcSEcCtD
Sorafenib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	8.15e-05	0.000459	CcSEcCtD
Sorafenib—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	8.13e-05	0.000458	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	8.13e-05	0.000458	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	8.12e-05	0.000458	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—peripheral nervous system neoplasm	8.05e-05	0.000453	CcSEcCtD
Sorafenib—Pain—Cisplatin—peripheral nervous system neoplasm	8.04e-05	0.000453	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.02e-05	0.000452	CcSEcCtD
Sorafenib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	7.94e-05	0.000447	CcSEcCtD
Sorafenib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	7.92e-05	0.000446	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	7.86e-05	0.000443	CcSEcCtD
Sorafenib—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	7.84e-05	0.000442	CcSEcCtD
Sorafenib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	7.81e-05	0.00044	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	7.71e-05	0.000434	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	7.68e-05	0.000433	CcSEcCtD
Sorafenib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	7.68e-05	0.000433	CcSEcCtD
Sorafenib—Asthenia—Vincristine—peripheral nervous system neoplasm	7.63e-05	0.00043	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	7.62e-05	0.000429	CcSEcCtD
Sorafenib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	7.57e-05	0.000427	CcSEcCtD
Sorafenib—Infestation—Epirubicin—peripheral nervous system neoplasm	7.57e-05	0.000427	CcSEcCtD
Sorafenib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	7.57e-05	0.000426	CcSEcCtD
Sorafenib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	7.55e-05	0.000426	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	7.51e-05	0.000423	CcSEcCtD
Sorafenib—Rash—Dactinomycin—peripheral nervous system neoplasm	7.51e-05	0.000423	CcSEcCtD
Sorafenib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	7.49e-05	0.000422	CcSEcCtD
Sorafenib—Renal failure—Epirubicin—peripheral nervous system neoplasm	7.44e-05	0.000419	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	7.44e-05	0.000419	CcSEcCtD
Sorafenib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	7.44e-05	0.000419	CcSEcCtD
Sorafenib—Fatigue—Etoposide—peripheral nervous system neoplasm	7.43e-05	0.000419	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	7.42e-05	0.000418	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	7.38e-05	0.000416	CcSEcCtD
Sorafenib—Jaundice—Epirubicin—peripheral nervous system neoplasm	7.38e-05	0.000416	CcSEcCtD
Sorafenib—Pain—Etoposide—peripheral nervous system neoplasm	7.37e-05	0.000415	CcSEcCtD
Sorafenib—Constipation—Etoposide—peripheral nervous system neoplasm	7.37e-05	0.000415	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	7.35e-05	0.000414	CcSEcCtD
Sorafenib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	7.3e-05	0.000411	CcSEcCtD
Sorafenib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	7.28e-05	0.00041	CcSEcCtD
Sorafenib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	7.16e-05	0.000404	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	7.14e-05	0.000402	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	7.11e-05	0.000401	CcSEcCtD
Sorafenib—Nausea—Dactinomycin—peripheral nervous system neoplasm	7.07e-05	0.000398	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	7.05e-05	0.000397	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	7.05e-05	0.000397	CcSEcCtD
Sorafenib—Dizziness—Vincristine—peripheral nervous system neoplasm	7.03e-05	0.000396	CcSEcCtD
Sorafenib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	7.02e-05	0.000395	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	7.01e-05	0.000395	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—peripheral nervous system neoplasm	7.01e-05	0.000395	CcSEcCtD
Sorafenib—Rash—Alitretinoin—peripheral nervous system neoplasm	6.96e-05	0.000392	CcSEcCtD
Sorafenib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	6.95e-05	0.000392	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	6.95e-05	0.000391	CcSEcCtD
Sorafenib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	6.93e-05	0.00039	CcSEcCtD
Sorafenib—Headache—Alitretinoin—peripheral nervous system neoplasm	6.92e-05	0.00039	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	6.89e-05	0.000388	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	6.87e-05	0.000387	CcSEcCtD
Sorafenib—Urticaria—Etoposide—peripheral nervous system neoplasm	6.85e-05	0.000386	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	6.83e-05	0.000385	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	6.83e-05	0.000385	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—peripheral nervous system neoplasm	6.83e-05	0.000385	CcSEcCtD
Sorafenib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	6.81e-05	0.000384	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	6.81e-05	0.000384	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	6.8e-05	0.000383	CcSEcCtD
Sorafenib—Vomiting—Vincristine—peripheral nervous system neoplasm	6.76e-05	0.000381	CcSEcCtD
Sorafenib—Asthenia—Cisplatin—peripheral nervous system neoplasm	6.75e-05	0.00038	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	6.71e-05	0.000378	CcSEcCtD
Sorafenib—Rash—Vincristine—peripheral nervous system neoplasm	6.71e-05	0.000378	CcSEcCtD
Sorafenib—Dermatitis—Vincristine—peripheral nervous system neoplasm	6.7e-05	0.000378	CcSEcCtD
Sorafenib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	6.68e-05	0.000376	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	6.66e-05	0.000375	CcSEcCtD
Sorafenib—Headache—Vincristine—peripheral nervous system neoplasm	6.66e-05	0.000375	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	6.63e-05	0.000373	CcSEcCtD
Sorafenib—CYP2D6—cerebellum—peripheral nervous system neoplasm	6.61e-05	0.00259	CbGeAlD
Sorafenib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	6.61e-05	0.000372	CcSEcCtD
Sorafenib—Nausea—Alitretinoin—peripheral nervous system neoplasm	6.56e-05	0.000369	CcSEcCtD
Sorafenib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	6.44e-05	0.000363	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	6.43e-05	0.000362	CcSEcCtD
Sorafenib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	6.35e-05	0.000358	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—peripheral nervous system neoplasm	6.34e-05	0.000357	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	6.32e-05	0.000356	CcSEcCtD
Sorafenib—Nausea—Vincristine—peripheral nervous system neoplasm	6.32e-05	0.000356	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	6.31e-05	0.000355	CcSEcCtD
Sorafenib—Flushing—Epirubicin—peripheral nervous system neoplasm	6.31e-05	0.000355	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	6.29e-05	0.000354	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	6.21e-05	0.00035	CcSEcCtD
Sorafenib—Asthenia—Etoposide—peripheral nervous system neoplasm	6.18e-05	0.000348	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	6.18e-05	0.000348	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	6.17e-05	0.000348	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	6.17e-05	0.000347	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	6.14e-05	0.000346	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	6.13e-05	0.000345	CcSEcCtD
Sorafenib—Pruritus—Etoposide—peripheral nervous system neoplasm	6.1e-05	0.000343	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	6.07e-05	0.000342	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—peripheral nervous system neoplasm	6.01e-05	0.000338	CcSEcCtD
Sorafenib—Vomiting—Cisplatin—peripheral nervous system neoplasm	5.98e-05	0.000337	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	5.96e-05	0.000336	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	5.95e-05	0.000335	CcSEcCtD
Sorafenib—Rash—Cisplatin—peripheral nervous system neoplasm	5.93e-05	0.000334	CcSEcCtD
Sorafenib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	5.93e-05	0.000334	CcSEcCtD
Sorafenib—Erythema—Epirubicin—peripheral nervous system neoplasm	5.92e-05	0.000333	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	5.92e-05	0.000333	CcSEcCtD
Sorafenib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	5.9e-05	0.000332	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	5.87e-05	0.00033	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	5.84e-05	0.000329	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—peripheral nervous system neoplasm	5.84e-05	0.000329	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	5.8e-05	0.000327	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	5.71e-05	0.000322	CcSEcCtD
Sorafenib—Dizziness—Etoposide—peripheral nervous system neoplasm	5.7e-05	0.000321	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	5.69e-05	0.000321	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	5.68e-05	0.00032	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.67e-05	0.000319	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	5.62e-05	0.000317	CcSEcCtD
Sorafenib—Nausea—Cisplatin—peripheral nervous system neoplasm	5.59e-05	0.000315	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	5.56e-05	0.000313	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	5.51e-05	0.000311	CcSEcCtD
Sorafenib—Vomiting—Etoposide—peripheral nervous system neoplasm	5.48e-05	0.000309	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—peripheral nervous system neoplasm	5.48e-05	0.000309	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	5.48e-05	0.000309	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—peripheral nervous system neoplasm	5.47e-05	0.000308	CcSEcCtD
Sorafenib—Rash—Etoposide—peripheral nervous system neoplasm	5.43e-05	0.000306	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—peripheral nervous system neoplasm	5.43e-05	0.000306	CcSEcCtD
Sorafenib—Headache—Etoposide—peripheral nervous system neoplasm	5.4e-05	0.000304	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000302	CcSEcCtD
Sorafenib—Syncope—Epirubicin—peripheral nervous system neoplasm	5.31e-05	0.000299	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	5.3e-05	0.000298	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	5.26e-05	0.000297	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	5.2e-05	0.000293	CcSEcCtD
Sorafenib—Cough—Epirubicin—peripheral nervous system neoplasm	5.16e-05	0.000291	CcSEcCtD
Sorafenib—Nausea—Etoposide—peripheral nervous system neoplasm	5.12e-05	0.000288	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—peripheral nervous system neoplasm	5.11e-05	0.000288	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	5.06e-05	0.000285	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—peripheral nervous system neoplasm	5.04e-05	0.000284	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	5.04e-05	0.000284	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	5e-05	0.000282	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	4.93e-05	0.000278	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—peripheral nervous system neoplasm	4.91e-05	0.000277	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	4.9e-05	0.000276	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	4.83e-05	0.000272	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	4.81e-05	0.000271	CcSEcCtD
Sorafenib—Infection—Epirubicin—peripheral nervous system neoplasm	4.8e-05	0.00027	CcSEcCtD
Sorafenib—Cough—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000269	CcSEcCtD
Sorafenib—ABCB1—cerebellum—peripheral nervous system neoplasm	4.76e-05	0.00186	CbGeAlD
Sorafenib—Shock—Epirubicin—peripheral nervous system neoplasm	4.75e-05	0.000268	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	4.74e-05	0.000267	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	4.73e-05	0.000266	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	4.73e-05	0.000266	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	4.69e-05	0.000264	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	4.66e-05	0.000263	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	4.66e-05	0.000263	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	4.63e-05	0.000261	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000259	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	4.56e-05	0.000257	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000252	CcSEcCtD
Sorafenib—Infection—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.00025	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	4.4e-05	0.000248	CcSEcCtD
Sorafenib—Shock—Doxorubicin—peripheral nervous system neoplasm	4.4e-05	0.000248	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	4.38e-05	0.000247	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	4.38e-05	0.000247	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.34e-05	0.000245	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.000243	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	4.26e-05	0.00024	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	4.25e-05	0.00024	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	4.2e-05	0.000237	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	4.17e-05	0.000235	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.16e-05	0.000235	CcSEcCtD
Sorafenib—Pain—Epirubicin—peripheral nervous system neoplasm	4.13e-05	0.000233	CcSEcCtD
Sorafenib—Constipation—Epirubicin—peripheral nervous system neoplasm	4.13e-05	0.000233	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	4.07e-05	0.000229	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.98e-05	0.000224	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	3.95e-05	0.000223	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.000222	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.89e-05	0.000219	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.86e-05	0.000217	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	3.85e-05	0.000217	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—peripheral nervous system neoplasm	3.84e-05	0.000216	CcSEcCtD
Sorafenib—Pain—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000215	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000215	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.000215	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.000215	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	3.65e-05	0.000206	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.0002	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—peripheral nervous system neoplasm	3.55e-05	0.0002	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	3.53e-05	0.000199	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.53e-05	0.000199	CcSEcCtD
Sorafenib—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.47e-05	0.000195	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.42e-05	0.000193	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.3e-05	0.000186	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.000186	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000181	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.00018	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000178	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.07e-05	0.000173	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.06e-05	0.000172	CcSEcCtD
Sorafenib—Rash—Epirubicin—peripheral nervous system neoplasm	3.05e-05	0.000172	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.04e-05	0.000171	CcSEcCtD
Sorafenib—Headache—Epirubicin—peripheral nervous system neoplasm	3.03e-05	0.00017	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	0.000167	CcSEcCtD
Sorafenib—Nausea—Epirubicin—peripheral nervous system neoplasm	2.87e-05	0.000162	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.84e-05	0.00016	CcSEcCtD
Sorafenib—Rash—Doxorubicin—peripheral nervous system neoplasm	2.82e-05	0.000159	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.82e-05	0.000159	CcSEcCtD
Sorafenib—Headache—Doxorubicin—peripheral nervous system neoplasm	2.8e-05	0.000158	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.65e-05	0.00015	CcSEcCtD
Sorafenib—KIT—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.43e-06	3.92e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.43e-06	3.92e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—NRAS—peripheral nervous system neoplasm	5.43e-06	3.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—peripheral nervous system neoplasm	5.43e-06	3.91e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.42e-06	3.91e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.4e-06	3.89e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—TH—peripheral nervous system neoplasm	5.39e-06	3.89e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.36e-06	3.87e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.35e-06	3.86e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.31e-06	3.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—HRAS—peripheral nervous system neoplasm	5.29e-06	3.82e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	5.27e-06	3.8e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.26e-06	3.8e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.26e-06	3.8e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.24e-06	3.78e-05	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.21e-06	3.76e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.21e-06	3.76e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.21e-06	3.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—HRAS—peripheral nervous system neoplasm	5.19e-06	3.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.15e-06	3.72e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.14e-06	3.71e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	5.13e-06	3.7e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	5.09e-06	3.67e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—ERBB2—peripheral nervous system neoplasm	5.07e-06	3.65e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.03e-06	3.63e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—MYC—peripheral nervous system neoplasm	5.03e-06	3.63e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—HRAS—peripheral nervous system neoplasm	5.01e-06	3.62e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	5.01e-06	3.61e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5e-06	3.6e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.99e-06	3.6e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.98e-06	3.59e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.98e-06	3.59e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.97e-06	3.58e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—NRAS—peripheral nervous system neoplasm	4.96e-06	3.58e-05	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.95e-06	3.57e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.93e-06	3.56e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NRAS—peripheral nervous system neoplasm	4.89e-06	3.53e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—NRAS—peripheral nervous system neoplasm	4.89e-06	3.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—ERBB2—peripheral nervous system neoplasm	4.89e-06	3.53e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	4.88e-06	3.52e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.87e-06	3.51e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	4.85e-06	3.5e-05	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—AKT1—peripheral nervous system neoplasm	4.77e-06	3.44e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	4.72e-06	3.4e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.71e-06	3.4e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	4.7e-06	3.39e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.69e-06	3.38e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	4.68e-06	3.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HRAS—peripheral nervous system neoplasm	4.67e-06	3.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—AKT1—peripheral nervous system neoplasm	4.67e-06	3.37e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NRAS—peripheral nervous system neoplasm	4.64e-06	3.35e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NRAS—peripheral nervous system neoplasm	4.63e-06	3.34e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.63e-06	3.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.63e-06	3.34e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MYC—peripheral nervous system neoplasm	4.62e-06	3.34e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.61e-06	3.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—AKT1—peripheral nervous system neoplasm	4.58e-06	3.31e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.57e-06	3.3e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	4.56e-06	3.29e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—NRAS—peripheral nervous system neoplasm	4.52e-06	3.26e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—ERBB2—peripheral nervous system neoplasm	4.51e-06	3.26e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.49e-06	3.24e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.49e-06	3.24e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	4.49e-06	3.24e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.45e-06	3.21e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—AKT1—peripheral nervous system neoplasm	4.43e-06	3.19e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GNAS—peripheral nervous system neoplasm	4.4e-06	3.17e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.4e-06	3.17e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.36e-06	3.14e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	4.33e-06	3.13e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ABCB1—peripheral nervous system neoplasm	4.32e-06	3.12e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	4.3e-06	3.1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NRAS—peripheral nervous system neoplasm	4.29e-06	3.09e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.28e-06	3.09e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NRAS—peripheral nervous system neoplasm	4.28e-06	3.09e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	4.23e-06	3.05e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	4.22e-06	3.04e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MYC—peripheral nervous system neoplasm	4.21e-06	3.04e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.19e-06	3.02e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.19e-06	3.02e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NRAS—peripheral nervous system neoplasm	4.17e-06	3.01e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.16e-06	3e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.16e-06	3e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.15e-06	2.99e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.13e-06	2.98e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.13e-06	2.98e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.08e-06	2.94e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	4.07e-06	2.94e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.07e-06	2.94e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.03e-06	2.91e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4e-06	2.89e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	4e-06	2.88e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MYC—peripheral nervous system neoplasm	3.99e-06	2.88e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	3.99e-06	2.87e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MYC—peripheral nervous system neoplasm	3.98e-06	2.87e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	3.98e-06	2.87e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—peripheral nervous system neoplasm	3.97e-06	2.86e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.96e-06	2.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.96e-06	2.86e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	3.95e-06	2.85e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.95e-06	2.85e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.94e-06	2.84e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.9e-06	2.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NRAS—peripheral nervous system neoplasm	3.85e-06	2.78e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.8e-06	2.74e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.8e-06	2.74e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.78e-06	2.72e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.78e-06	2.72e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.77e-06	2.72e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	3.75e-06	2.7e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	3.73e-06	2.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NRAS—peripheral nervous system neoplasm	3.72e-06	2.68e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	3.71e-06	2.68e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	3.66e-06	2.64e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—peripheral nervous system neoplasm	3.63e-06	2.62e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—peripheral nervous system neoplasm	3.59e-06	2.59e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.58e-06	2.58e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—peripheral nervous system neoplasm	3.58e-06	2.58e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—peripheral nervous system neoplasm	3.58e-06	2.58e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.57e-06	2.58e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.55e-06	2.56e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.51e-06	2.54e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.51e-06	2.53e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—peripheral nervous system neoplasm	3.51e-06	2.53e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—peripheral nervous system neoplasm	3.49e-06	2.51e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.48e-06	2.51e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.45e-06	2.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NRAS—peripheral nervous system neoplasm	3.43e-06	2.48e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—peripheral nervous system neoplasm	3.4e-06	2.45e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—peripheral nervous system neoplasm	3.39e-06	2.44e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.38e-06	2.44e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	3.38e-06	2.44e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	3.33e-06	2.4e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—peripheral nervous system neoplasm	3.31e-06	2.38e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.27e-06	2.36e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	3.26e-06	2.35e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	3.25e-06	2.34e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.24e-06	2.34e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.22e-06	2.32e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.22e-06	2.32e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—peripheral nervous system neoplasm	3.21e-06	2.31e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.2e-06	2.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—peripheral nervous system neoplasm	3.2e-06	2.31e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.19e-06	2.3e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	3.17e-06	2.29e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.16e-06	2.28e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.16e-06	2.28e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—peripheral nervous system neoplasm	3.16e-06	2.28e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—peripheral nervous system neoplasm	3.16e-06	2.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.16e-06	2.28e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—peripheral nervous system neoplasm	3.14e-06	2.26e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—peripheral nervous system neoplasm	3.13e-06	2.26e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.12e-06	2.25e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.1e-06	2.24e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	3.08e-06	2.22e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.07e-06	2.21e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.06e-06	2.21e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	3.06e-06	2.21e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—peripheral nervous system neoplasm	3.05e-06	2.2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	3.03e-06	2.19e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3e-06	2.17e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	3e-06	2.17e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—peripheral nervous system neoplasm	3e-06	2.16e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3e-06	2.16e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—peripheral nervous system neoplasm	2.99e-06	2.16e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.99e-06	2.15e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.98e-06	2.15e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	2.98e-06	2.15e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.95e-06	2.13e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.95e-06	2.13e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—peripheral nervous system neoplasm	2.92e-06	2.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.87e-06	2.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—peripheral nervous system neoplasm	2.82e-06	2.03e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.81e-06	2.03e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.8e-06	2.02e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.79e-06	2.01e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—peripheral nervous system neoplasm	2.77e-06	2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—peripheral nervous system neoplasm	2.76e-06	1.99e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.73e-06	1.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—peripheral nervous system neoplasm	2.72e-06	1.96e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.71e-06	1.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.7e-06	1.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—peripheral nervous system neoplasm	2.7e-06	1.94e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.68e-06	1.94e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.66e-06	1.92e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.64e-06	1.9e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.63e-06	1.9e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	2.61e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	2.59e-06	1.87e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.57e-06	1.86e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.57e-06	1.85e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.57e-06	1.85e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.54e-06	1.83e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	2.54e-06	1.83e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.51e-06	1.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—peripheral nervous system neoplasm	2.51e-06	1.81e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.5e-06	1.8e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—peripheral nervous system neoplasm	2.49e-06	1.8e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.49e-06	1.79e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.48e-06	1.79e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	2.45e-06	1.77e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.42e-06	1.75e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.42e-06	1.75e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.41e-06	1.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—peripheral nervous system neoplasm	2.4e-06	1.73e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.4e-06	1.73e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.31e-06	1.67e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.31e-06	1.67e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.3e-06	1.66e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.29e-06	1.65e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.27e-06	1.64e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.27e-06	1.64e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.25e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.24e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—peripheral nervous system neoplasm	2.22e-06	1.6e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.2e-06	1.58e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.19e-06	1.58e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.08e-06	1.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.06e-06	1.49e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.04e-06	1.47e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.04e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	2e-06	1.44e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.97e-06	1.42e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.97e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.96e-06	1.42e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.94e-06	1.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.93e-06	1.4e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.93e-06	1.39e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—peripheral nervous system neoplasm	1.91e-06	1.38e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—peripheral nervous system neoplasm	1.91e-06	1.38e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.88e-06	1.36e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.84e-06	1.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.76e-06	1.27e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.74e-06	1.26e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.66e-06	1.2e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.62e-06	1.17e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	1.61e-06	1.16e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.59e-06	1.15e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.55e-06	1.12e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.52e-06	1.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.34e-06	9.67e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—peripheral nervous system neoplasm	1.19e-06	8.57e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	1.16e-06	8.38e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	1.01e-06	7.25e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	8.98e-07	6.48e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	8.76e-07	6.32e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	8.26e-07	5.96e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	8.19e-07	5.9e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	6.99e-07	5.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	5.4e-07	3.89e-06	CbGpPWpGaD
